Target intelligence / Profile preview

Phosphodiesterase 10A1 (PDE10A)

Target: PDE10A
Molecular classification: Enzyme, Phosphodiesterase

Overview

Phosphodiesterase 10A1 (PDE10A) is an enzyme that hydrolyzes both cAMP and cGMP, thereby regulating their signaling actions. It is highly expressed in the brain, particularly in the striatum, making it a relevant target for neuropsychiatric disorders such as schizophrenia. Inhibition of PDE10A is being explored as a therapeutic strategy.

Other names: PDE10

Mechanism of action

Inhibition of PDE10A leads to increased levels of cAMP and cGMP in the striatum, modulating dopamine signaling.

Biological functions

Signal transductionRegulation of cAMP levelsRegulation of cGMP levels

Disease associations

SchizophreniaObesityNeurological disorders

Interacting drugs

AMG-579

7 more in the full profile.

Beyond the preview

Go deeper on Phosphodiesterase 10A1 (PDE10A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phosphodiesterase 10A1 (PDE10A).

Explore the full profile